MAGE: The spell is broken

Katayoun Rezvan

doi:10.1158/1078-0432.CCR-11-2302

MAGE: The spell is broken

Katayoun Rezvan

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.

Original language	English (US)
Pages (from-to)	6955-6957
Number of pages	3
Journal	Clinical Cancer Research
Volume	17
Issue number	22
DOIs	https://doi.org/10.1158/1078-0432.CCR-11-2302
State	Published - Nov 15 2011
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-11-2302

Cite this

@article{a0cec5437175456fa5b1c20f1ee0de48,

title = "MAGE: The spell is broken",

abstract = "The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.",

author = "Katayoun Rezvan",

year = "2011",

month = nov,

day = "15",

doi = "10.1158/1078-0432.CCR-11-2302",

language = "English (US)",

volume = "17",

pages = "6955--6957",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "22",

}

TY - JOUR

T1 - MAGE

T2 - The spell is broken

AU - Rezvan, Katayoun

PY - 2011/11/15

Y1 - 2011/11/15

N2 - The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.

AB - The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=81255138493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255138493&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2302

DO - 10.1158/1078-0432.CCR-11-2302

M3 - Comment/debate

C2 - 22068655

AN - SCOPUS:81255138493

SN - 1078-0432

VL - 17

SP - 6955

EP - 6957

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 22

ER -

MAGE: The spell is broken

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this